Inhibition of CCR1 and CCR5 by antagonists or neutralizing antibodies partially reduces osteoclastogenesis, osteolytic lesions and MM-induced angiogenesis [41,84,86,114]. Here, CCR5 is linked to Miyoshi myopathy.